Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.
Result: Thirty-four drug-naive patients (14.5%) carried the RT mutation A62V.
Table: A62V
Discussion: The influence of the A62V mutation and other secondary mutations on long-term cART outcomes is also still unresolved.
Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.
Method: The following non-polymorphic ARV-selected mutations were classified as drug resistance mutations (DRM): (i) the NRTI resistance mutations M41L, A62V, K65RN, D67NG, T69D, T69 insertions, T69 deletion, K70REGQ, L74VI, V75MT, F77L, Y115F, F116Y, Q151M, M184VI, L210W, T215YFSDCIV, and K219QENR; (ii) the
HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana.
Result: In our study, other NRTI-RAMs known to be associated with Q151M-mediated multi-nucleoside resistance including A62V, V75I, F77L, and F116Y, were also significantly more common in patients harboring the Q151M mutation (p<0.001).
Increasing trends in primary NNRTI resistance among newly HIV-1-diagnosed individuals in Buenos Aires, Argentina.
PMID: 24093951
2013
Journal of the International AIDS Society
Method: Sequences were analyzed to identify mutations associated with reduced susceptibility to protease and RT inhibitors, as reported by the International AIDS Society-USA in 2010: RT-M41L, A62V, K65R, D67N, 69 insert, K70R, L74V,V75I, F77L, L100I, K101P, K103N, V106A, V106M, V108I, Y115F, F116Y,
Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan.
Result: As summarized in Table 2, all resistant mutations were found as sole mutation, one with A62V, one with D67E and six cases of intermediates at codon 215 (one with T215D, one with T215E, two cases of T215L and two cases of T215S), one with N88D and 14 cases of M46I mutation were detected by conventional bulk sequencing analysis, yielding a drug resistance mutation prevalence of 15.4% (23/149 cases) (Table 2).
Result: The identified A62V, D67E, T215E, T215S and N88D mutations detected by bulk sequencing were not targeted by AS-PCR, and th
Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.
Discussion: In HIV, decreased binding of AZT is conferred initially in the presence of the primary Q151M mutation, followed by secondary mutations F77L, A62V, V75I and F116Y.
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.
Result: At time of failure the following NRTI mutations were observed: A62V (n=1; 1%), K65R (n=2; 3%), D67G/N (n=2; 3%), T69L (n=1; 1%), K70R (n=1; 1%), V75I (n=1; 1%), M184V (n=46; 66%) and K219K (n=1; 1%).
Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City.
PMID: 22592583
2012
Journal of acquired immune deficiency syndromes (1999)
4Method: ARV resistance was defined by mutations at the following positions: M41L, A62V, K65R, D67N, T69ins, K70R, L74VI, Y115F, F116Y, Q151M, M184VI, T210W, T215YF and K219QE for Nucleoside Reverse Transcriptase Inhibitors (NRTI), L100I, K101EP, K103NS, V106AM
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
PMID: 22784038
2012
The New England journal of medicine
Abstract: K65R, M184V, and A62V resistance mutations developed in 1 participant in the TDF-FTC group who had had an unrecognized acute HIV infection at enrollment.
HIV mutation literature information.
PMID: 
2013
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT